Compare Incyte Corporation (INCY) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Incyte Corporation trades at $115.81 (market cap $23.44B), while GraniteShares 2x Long NVDA Daily ETF trades at $33.19. The key difference: Incyte Corporation is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| INCY | NVDL | |
|---|---|---|
Market Cap | $23.44B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $118.52 | $43.02 |
52-Week Low | $68.90 | $21.76 |
Enterprise Value | $19.46B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $30.51 with a 0.76% daily gain, though technical indicators signal a bearish trend. The fund provides 2x daily leveraged exposure to NVIDIA's stock performance, experiencing significant volatility with a recent 12% single-day drop. Recent corporate actions include two 1:3 stock splits scheduled for June 2026.
The outlook remains tied to NVIDIA's AI-driven growth but carries substantial risk from daily leverage reset mechanics. While the fund has delivered strong YTD returns of 12.66%, historical volatility highlights the compounding risks during market downturns. Investors face amplified losses during NVIDIA price declines despite potential for outsized gains in bullish periods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
